# JAK2

## Overview
JAK2, or Janus kinase 2, is a gene that encodes for the protein tyrosine kinase known as Janus kinase 2. This protein is a crucial component of the JAK-STAT signaling pathway, which is vital for the regulation of gene expression in response to cytokines and growth factors. The JAK2 protein itself is characterized by several functional domains, including a kinase domain that catalyzes the phosphorylation of target proteins, and a pseudokinase domain that regulates its kinase activity. Mutations in the JAK2 gene, such as the V617F mutation, have been linked to various myeloproliferative neoplasms, highlighting its importance in cellular signaling and disease (QuintÃ¡s-Cardama2013Molecular; Levine2007Role). As a kinase, JAK2 is involved in multiple signaling pathways beyond JAK-STAT, influencing processes such as cell growth, hematopoiesis, and immune function (Perner2019Roles).

## Structure
The molecular structure of the human Janus kinase 2 (JAK2) protein is characterized by several distinct domains that are crucial for its function. The N-terminal FERM domain mediates specific binding to cytokine receptors and assists in the cell surface expression of these receptors (Giordanetto2002Prediction; Saharinen2002The). This is followed by an SH2-like domain, which, although structurally present, is predicted not to be fully functional (Giordanetto2002Prediction). The central region of JAK2 contains a pseudokinase domain (JH2), which, despite lacking conserved active site residues necessary for catalysis, still exhibits regulatory catalytic activity (Toms2013Structure; Bandaranayake2012Crystal). This domain plays a critical role in regulating the kinase activity of JAK2 by maintaining a low basal activity level in the absence of cytokines and is the site of the V617F mutation associated with myeloproliferative neoplasms (Hubbard2018Mechanistic). The C-terminal region comprises the JH1 domain, a catalytically active tyrosine kinase domain responsible for the enzyme's catalytic activity, including the trans-phosphorylation of specific tyrosine residues essential for JAK2 activation and subsequent signaling (Saharinen2003Autoinhibition).

Post-translational modifications of JAK2 include phosphorylation at several tyrosine residues in the kinase activation loop, which significantly influences the activity of JAK2 (Saharinen2002The). The protein also undergoes autophosphorylation at Ser523 and Tyr570, which are autoinhibitory phosphorylation sites (Toms2013Structure).

The structural arrangement of these domains and their interactions are critical for the function and regulation of JAK2, including its role in the JAK-STAT signaling pathway. The inter-domain orientations within JAK2 suggest specific spatial arrangements that could be critical for its function, as indicated by molecular dynamics simulations and docking studies (Giordanetto2002Prediction).

## Function
JAK2 (Janus kinase 2) is a protein tyrosine kinase that plays a pivotal role in the signaling pathways of various cytokines and growth factors, which are essential for hematopoiesis and immune function. In healthy human cells, JAK2 is primarily involved in the JAK-STAT signaling pathway. Upon activation by cytokines, JAK2 phosphorylates STAT (Signal Transducers and Activators of Transcription) proteins, which then dimerize and translocate to the nucleus to influence gene expression. This process is crucial for the regulation of immune responses, the growth and development of various cell types within the hematopoietic lineage, and maintaining cellular functions in response to environmental signals (Perner2019Roles).

JAK2 is particularly important in the signaling pathways of cytokines such as erythropoietin, thrombopoietin, and various interleukins, which are critical for the proliferation, differentiation, and function of blood cells. It mediates cellular responses to external signals through additional pathways like the Mitogen-activated protein kinases (MAPK) and the Protein kinase B pathway (PI3K/AKT), further underscoring its role in cell biology and organismal outcomes (Perner2019Roles).

Moreover, JAK2's activity is essential for maintaining a balance in the differentiation potential towards myeloid and lymphoid progenitor cells in normal hematopoietic stem cells, which is critical for the proper function and self-renewal of these cells (Perner2019Roles).

## Clinical Significance
Mutations in the JAK2 gene, particularly the V617F mutation, are significantly associated with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). These conditions are characterized by the excessive proliferation of myeloid cells, which can lead to severe complications such as thrombosis and splenomegaly. The V617F mutation, resulting from a single base G to T transversion at codon 617, leads to a valine-to-phenylalanine substitution that disrupts the autoinhibitory activity of JAK2, causing constitutive activation of the kinase domain (Morgan2008A; QuintÃ¡s-Cardama2013Molecular).

This mutation is present in about 95% of patients with PV, and 50%-60% of those with ET or MF. It is also associated with a higher incidence of thrombosis and influences the transformation of ET into PV (Dahabreh2009Is). Beyond hematologic malignancies, the JAK/STAT pathway, often activated by JAK2, plays a role in solid tumors like breast, lung, and head and neck cancers, typically through increased cytokine signaling (QuintÃ¡s-Cardama2013Molecular).

The discovery of the JAK2 V617F mutation has not only enhanced the understanding of the pathogenesis of these disorders but also underscored the importance of the JAK-STAT signaling pathway in myeloid differentiation and the development of targeted therapies such as JAK2 inhibitors (Levine2007Role).

## Interactions
JAK2 (Janus kinase 2) interacts with various proteins and receptors to mediate signaling pathways crucial for cell growth, development, and immune responses. One of the primary interactions of JAK2 is with the growth hormone receptor (GHR). Upon binding of the growth hormone, GHR undergoes structural changes that facilitate the activation of JAK2. This process involves the separation of the Box1 sequences within the receptor, allowing the kinase domains of JAK2 to come into proximity and activate through trans-phosphorylation (Brooks2014Mechanism).

Additionally, JAK2 plays a significant role in the internalization and regulation of the iron exporter ferroportin (Fpn) in response to hepcidin binding. Hepcidin binding to Fpn induces its dimerization, which is necessary for JAK2 activation. This interaction leads to the phosphorylation of Fpn, crucial for its internalization and the regulation of iron metabolism (De2009Hepcidin-induced).

JAK2 also interacts with the erythropoietin receptor (EpoR). The FERM domain of JAK2 is essential for its association with EpoR, a key step in JAK2 activation. This interaction leads to structural changes in JAK2, relieving inhibitory constraints within the kinase and enabling its activation (Funakoshi-Tago2008Jak2). These interactions highlight the diverse roles of JAK2 in cellular signaling and its importance in various biological processes.


## References


[1. (Dahabreh2009Is) Issa J. Dahabreh, Katerina Zoi, Stavroula Giannouli, Christine Zoi, Dimitrios Loukopoulos, and Michael Voulgarelis. Is jak2 v617f mutation more than a diagnostic index? Leukemia Research, 33(1):67â73, January 2009. URL: http://dx.doi.org/10.1016/j.leukres.2008.06.006, doi:10.1016/j.leukres.2008.06.006. (147 citations) 10.1016/j.leukres.2008.06.006](https://doi.org/10.1016/j.leukres.2008.06.006)

[2. (Levine2007Role) Ross L. Levine, Animesh Pardanani, Ayalew Tefferi, and D. Gary Gilliland. Role of jak2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews Cancer, 7(9):673â683, September 2007. URL: http://dx.doi.org/10.1038/nrc2210, doi:10.1038/nrc2210. (743 citations) 10.1038/nrc2210](https://doi.org/10.1038/nrc2210)

[3. (Saharinen2002The) Pipsa Saharinen and Olli Silvennoinen. The pseudokinase domain is required for suppression of basal activity of jak2 and jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. Journal of Biological Chemistry, 277(49):47954â47963, December 2002. URL: http://dx.doi.org/10.1074/jbc.m205156200, doi:10.1074/jbc.m205156200. (254 citations) 10.1074/jbc.m205156200](https://doi.org/10.1074/jbc.m205156200)

[4. (Perner2019Roles) Perner, Perner, Ernst, and Heidel. Roles of jak2 in aging, inflammation, hematopoiesis and malignant transformation. Cells, 8(8):854, August 2019. URL: http://dx.doi.org/10.3390/cells8080854, doi:10.3390/cells8080854. (164 citations) 10.3390/cells8080854](https://doi.org/10.3390/cells8080854)

[5. (Saharinen2003Autoinhibition) Pipsa Saharinen, Mauno Vihinen, and Olli Silvennoinen. Autoinhibition of jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Molecular Biology of the Cell, 14(4):1448â1459, April 2003. URL: http://dx.doi.org/10.1091/mbc.E02-06-0342, doi:10.1091/mbc.e02-06-0342. (298 citations) 10.1091/mbc.E02-06-0342](https://doi.org/10.1091/mbc.E02-06-0342)

[6. (De2009Hepcidin-induced) Ivana De Domenico, Eric Lo, Diane M. Ward, and Jerry Kaplan. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with jak2. Proceedings of the National Academy of Sciences, 106(10):3800â3805, March 2009. URL: http://dx.doi.org/10.1073/pnas.0900453106, doi:10.1073/pnas.0900453106. (191 citations) 10.1073/pnas.0900453106](https://doi.org/10.1073/pnas.0900453106)

[7. (QuintÃ¡s-Cardama2013Molecular) Alfonso QuintÃ¡s-Cardama and Srdan Verstovsek. Molecular pathways: jak/stat pathway: mutations, inhibitors, and resistance. Clinical Cancer Research, 19(8):1933â1940, April 2013. URL: http://dx.doi.org/10.1158/1078-0432.ccr-12-0284, doi:10.1158/1078-0432.ccr-12-0284. (225 citations) 10.1158/1078-0432.ccr-12-0284](https://doi.org/10.1158/1078-0432.ccr-12-0284)

[8. (Brooks2014Mechanism) Andrew J. Brooks, Wei Dai, Megan L. OâMara, Daniel Abankwa, Yash Chhabra, Rebecca A. Pelekanos, Olivier Gardon, Kathryn A. Tunny, Kristopher M. Blucher, Craig J. Morton, Michael W. Parker, Emma Sierecki, Yann Gambin, Guillermo A. Gomez, Kirill Alexandrov, Ian A. Wilson, Manolis Doxastakis, Alan E. Mark, and Michael J. Waters. Mechanism of activation of protein kinase jak2 by the growth hormone receptor. Science, May 2014. URL: http://dx.doi.org/10.1126/science.1249783, doi:10.1126/science.1249783. (440 citations) 10.1126/science.1249783](https://doi.org/10.1126/science.1249783)

[9. (Giordanetto2002Prediction) Fabrizio Giordanetto and Romano T. Kroemer. Prediction of the structure of human janus kinase 2 (jak2) comprising jak homology domains 1 through 7. Protein Engineering, Design and Selection, 15(9):727â737, September 2002. URL: http://dx.doi.org/10.1093/protein/15.9.727, doi:10.1093/protein/15.9.727. (122 citations) 10.1093/protein/15.9.727](https://doi.org/10.1093/protein/15.9.727)

[10. (Funakoshi-Tago2008Jak2) Megumi Funakoshi-Tago, StÃ©phane Pelletier, Hiroshi Moritake, Evan Parganas, and James N. Ihle. Jak2 ferm domain interaction with the erythropoietin receptor regulates jak2 kinase activity. Molecular and Cellular Biology, 28(5):1792â1801, March 2008. URL: http://dx.doi.org/10.1128/mcb.01447-07, doi:10.1128/mcb.01447-07. (67 citations) 10.1128/mcb.01447-07](https://doi.org/10.1128/mcb.01447-07)

[11. (Hubbard2018Mechanistic) Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, January 2018. URL: http://dx.doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. (98 citations) 10.3389/fendo.2017.00361](https://doi.org/10.3389/fendo.2017.00361)

[12. (Toms2013Structure) Angela V Toms, Anagha Deshpande, Randall McNally, Youngjee Jeong, Julia M Rogers, Chae Un Kim, Sol M Gruner, Scott B Ficarro, Jarrod A Marto, Martin Sattler, James D Griffin, and Michael J Eck. Structure of a pseudokinase-domain switch that controls oncogenic activation of jak kinases. Nature Structural &amp; Molecular Biology, 20(10):1221â1223, September 2013. URL: http://dx.doi.org/10.1038/nsmb.2673, doi:10.1038/nsmb.2673. (84 citations) 10.1038/nsmb.2673](https://doi.org/10.1038/nsmb.2673)

[13. (Morgan2008A) Kelly J. Morgan and D. Gary Gilliland. A role for jak2 mutations in myeloproliferative diseases. Annual Review of Medicine, 59(1):213â222, February 2008. URL: http://dx.doi.org/10.1146/annurev.med.59.061506.154159, doi:10.1146/annurev.med.59.061506.154159. (122 citations) 10.1146/annurev.med.59.061506.154159](https://doi.org/10.1146/annurev.med.59.061506.154159)

[14. (Bandaranayake2012Crystal) Rajintha M Bandaranayake, Daniela Ungureanu, Yibing Shan, David E Shaw, Olli Silvennoinen, and Stevan R Hubbard. Crystal structures of the jak2 pseudokinase domain and the pathogenic mutant v617f. Nature Structural &amp; Molecular Biology, 19(8):754â759, July 2012. URL: http://dx.doi.org/10.1038/nsmb.2348, doi:10.1038/nsmb.2348. (265 citations) 10.1038/nsmb.2348](https://doi.org/10.1038/nsmb.2348)